- Aktuelle Seite:
-
Home
-
Substitutionsmittel
- Verschiedenes
Change in alcohol and other drug use during five years of continuous opioid substitution treatment
Brian Eastwood, John Strang and John Marsden
Drug and Alcohol Dependence, Volume 194, 1 January 2019, Pages 438-446, doi.org/10.1016/j.drugalcdep.2018.11.008
https://www.sciencedirect.com/science/article/pii/S0376871618304897#bib0100
Substitution von A bis Z
Mit der vorliegenden Broschüre möchten wir Ihnen ein Nachschlagewerk an die Hand geben, welches die Grundlagen der Suchttherapie von A bis Z vermittelt und Ihnen daher im Alltag ein hilfreicher Begleiter sein kann. Vor allem Personen, die noch wenig Erfahrung mit der Substitutionsbehandlung haben, sollen unterstützt werden, sich schnell in das Therapiegebiet einzufinden und die Arbeitsabläufe kennen zu lernen. (Hexal, 2018)
Alternative Opioid Agonists in the Treatment of Opioid Dependence: A Systematic Review [Internet].
Mosdøl A, Ding KY, Hov L.
Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Mar 8.
https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0098799/
Sanofi Kompendium Substitutionsmedizin – Neuauflage 2018
Das neue Kompendium Substitutionsmedizin bietet allen Ärzten, die in der Praxis mit Suchtmedizin zu tun haben, einen umfassenden Einblick in die verschiedenen Aspekte der Opiatsubstitutionstherapie. Das Kompendium wurde erweitert um die aktuelle Rechtslage und richtet sich auch an ApothekerInnen als zusätzliche Zielgruppe
Das Kompendium kann aufgerufen und runtergeladen werden auf der Substitutionsseite von Sanofi. Die Druckausgabe kann über den Außendienst von Sanofi bestellt werden.
https://www.substitutionsportal.de/
Unsupervised Intake of Medicines for Individuals in Opioid Maintenance [Internet].
Hov L, Mosdøl A, Ding Y, Strømme H, Vist GE.
Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2016 Sep.
https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0098764/
One size does not fit all – evolution of opioid agonist treatments in a naturalistic setting over 23 years.
Nordt, C., Vogel, M., Dey, M., Moldovanyi, A., Beck, T., Berthel, T., Walter, M., Seifritz, E., Dürsteler, K. M., and Herdener, M. (2018)
Addiction, doi.org/10.1111/add.14442.
Abstract
https://onlinelibrary.wiley.com/doi/10.1111/add.14442
Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.
Bansback, N., Guh, D., Oviedo-Joekes, E., Brissette, S., Harrison, S., Janmohamed, A., Krausz, M., MacDonald, S., Marsh, D. C., Schechter, M. T., and Anis, A. H. (2018)
Addiction, doi: 10.1111/add.14171.
Abstract
https://onlinelibrary.wiley.com/doi/abs/10.1111/add.14171
SAMHSA. Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families: Treatment Improvement Protocol: TIP 63.
Substance Abuse and Mental Health Services Administration
[US] Substance Abuse and Mental Health Services Administration, 2018
https://store.samhsa.gov/shin/content/SMA18-5063FULLDOC/SMA18-5063FULLDOC.pdf
Neue Auflage: Leitfaden für Ärzte zur substitutionsgestützten Behandlung Opiatabhängiger (Bayerische Akademie für Sucht- und Gesundheitsfragen)
Die 4. vollständig überarbeitete Auflage der BAS-Publikation "Leitfaden für Ärzte zur substitutionsgestützten Behandlung Opiatabhängiger" steht Ihnen ab sofort zum Download zur Verfügung.
Hierbei wurden die neue BtMVV (2017) sowie die überarbeiteten Richtlinien der Bundesärztekammer (2017) berücksichtigt. (BAS, Januar 2018)
Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study.
Larney S, Hickman M, Fiellin DA, Dobbins T, Nielsen S, Jones NR, Mattick RP, Ali R, Degenhardt L.
BMJ Open. 2018 Aug 5;8(8):e025204. doi: 10.1136/bmjopen-2018-025204.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078240/
Handbuch Substitutionsbehandlung in Oberösterreich
Sachverständigenkommission zur regionalen Koordination der Substitutionsbehandlung
Linz, 2016, Version 2.0
Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.
Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, Hser YI.
J Neuroimmune Pharmacol. 2018 Aug 9. doi: 10.1007/s11481-018-9801-x.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30094695
Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities
Dennis McCarty, Kelsey C. Priest, P. Todd Korthuis
Annual Review of Public Health 2018 39:1
http://www.annualreviews.org/doi/pdf/10.1146/annurev-publhealth-040617-013526
USA. FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder
The U.S. Food and Drug Administration today issued new scientific recommendations aimed at encouraging more widespread innovation and development of novel medication-assisted treatment (MAT) drugs for the treatment of opioid use disorder (OUD). New draft guidance issued today outlines new ways for drug developers to consider measuring and demonstrating the effectiveness and benefits of new or existing MAT products. This new draft guidance is part of the FDA’s ongoing commitment to promote more widespread development, access to and adoption of MAT. (FDA, 06.08.2018)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm615892.htm
Tramadol for maintenance in opioid dependence: A retrospective chart review.
Sarkar S, Lal R, Varshney M, Balhara YPS.
J Opioid Manag. 2017 Sep/Oct;13(5):329-334. doi: 10.5055/jom.2017.0401.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29199398
Pharmacological therapies for management of opium withdrawal.
Rahimi-Movaghar A, Gholami J, Amato L, Hoseinie L, Yousefi-Nooraie R, Amin-Esmaeili M.
Cochrane Database Syst Rev. 2018 Jun 21;6:CD007522. doi: 10.1002/14651858.CD007522.pub2. Review.
Abstract
Kanada. B.C. pilot project to distribute clean opioids to people at high risk of overdose
Ottawa has approved a pilot project that will allow health officials in B.C. to distribute clean opioids to drug users to use as they please, marking one of the province's most radical efforts to address a fentanyl-saturated drug supply that has killed more than 1,000 people this year. (Globe and Mail, 19.12.2017)
Snake Venom Use as a Substitute for Opioids: A Case Report and Review of Literature.
Mehra A, Basu D, Grover S.
Indian J Psychol Med. 2018 May-Jun;40(3):269-271. doi: 10.4103/IJPSYM.IJPSYM_216_17.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968650/
Betäubungsmittel: Arzneimittel zur Substitution – ein Überblick
Bei der Substitutionstherapie Opioidabhängiger gibt es eine Reihe zusätzlicher Auflagen. Hier sind vor allem die Regelungen des § 5 der Betäubungsmittelverschreibungsverordnung maßgeblich. Unter anderem finden sich dort Vorgaben, welche Arzneimittel beziehungsweise Wirkstoffe überhaupt für eine Substitutionstherapie verschrieben werden können. In der Praxis stehen sowohl Rezepturen als auch Fertigarzneimittel zur Verfügung. (DAZ – Deutsche Apotheker Zeitung, 11.12.2017)
Continuous opioid substitution treatment over five years: Heroin use trajectories and outcomes.
Eastwood B, Strang J, Marsden J.
Drug Alcohol Depend. 2018 May 16;188:200-208. doi: 10.1016/j.drugalcdep.2018.03.052.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29778774
Opioid Agonist Treatment Reduces Societal Costs of Crime
Patients with opioid use disorder generated crime-related costs to society at a lower rate while they were in treatment compared with after they left treatment.
Patients who initiate time-unlimited opioid-agonist therapy will generate lower average total crime-related costs over the next 6 months than patients who initiate a 21-day detoxification regimen.
Savings in crime-related costs are substantial and warrant inclusion in cost-effectiveness analyses of treatment for opioid addiction. (NIDA Notes, Eric Sarlin, M.Ed., M.A., 23.08.2017)
Opioid substitution treatment and heroin dependent adolescents: reductions in heroin use and treatment retention over twelve months.
Smyth BP, Elmusharaf K, Cullen W.
BMC Pediatr. 2018 May 4;18(1):151. doi: 10.1186/s12887-018-1137-4.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936020/
A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence.
Chetty M, Kenworthy JJ, Langham S, Walker A, Dunlop WC.
Addict Sci Clin Pract. 2017 Feb 24;12(1):6. doi: 10.1186/s13722-017-0071-3. Review.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324212/
USA. Lofexidine: FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults
Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority. (FDA, USA, 16.05.2018)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607884.htm
The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada.
Franklyn AM, Eibl JK, Gauthier GJ, Marsh DC (2017)
PLoS ONE12(11): e0187633. doi.org/10.1371/journal.pone.0187633
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0187633
Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review.
Maglione MA, Raaen L, Chen C, Azhar G, Shahidinia N, Shen M, Maksabedian E, Shanman RM, Newberry S, Hempel S.
J Subst Abuse Treat. 2018 Jun;89:28-51. doi: 10.1016/j.jsat.2018.03.001. Epub 2018 Mar 13.
https://linkinghub.elsevier.com/retrieve/pii/S0740-5472(17)30482-8
Medications for opioid use disorder: bridging the gap in care
Volkow, Nora D
The Lancet , Volume 0 , Issue 0 , Published: 14 November 2017
doi.org/10.1016/S0140-6736(17)32893-3
Abstract
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32893-3/fulltext
Characteristics of opioid-maintained clients smoking fentanyl patches: The importance of confirmatory drug analysis illustrated by a case series and mini-review.
Kimergård A, Dunne J, Bøgen A, Hindersson P, Breindahl T.
Drug Test Anal. 2018 Apr 19. doi: 10.1002/dta.2397.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29675893
USA. Fact Sheet: Medication-Assisted Treatment Improves Outcomes for Patients With Opioid Use Disorder
Overview
Opioid overdoses cause one death every 20 minutes. Medication-assisted treatment (MAT)—a combination of psychosocial therapy and U.S. Food and Drug Administration-approved medication—is the most effective intervention to treat opioid use disorder (OUD) and is more effective than either behavioral interventions or medication alone. MAT significantly reduces illicit opioid use compared with nondrug approaches, and increased access to these therapies can reduce overdose fatalities. However, MAT is often unavailable to those in need of it because of inadequate funding for treatment programs and a lack of qualified providers who can deliver these therapies.
(Fact Sheet, Substance Use Prevention and Treatment Initiative, 22.11.2016)
Listening to Patients’ Voices in Developing New Opioid Addiction Treatments.
NIDA. (2018, April 5).
Seite 1 von 3
